Literature DB >> 34756156

Integrating real world data and clinical trial results using survival data reconstruction and marginal moment-balancing weights.

Kylie Getz1,2, Ronac Mamtani3, Rebecca A Hubbard1,3.   

Abstract

Outcomes in electronic health records (EHR)-derived cohorts can be compared to similarly treated clinical trial cohorts to estimate the efficacy-effectiveness gap, the discrepancy in performance of an intervention in a trial compared to the real world. However, because clinical trial data may only be available in the form of published summary statistics and Kaplan-Meier curves, survival data reconstruction methods are needed to recreate individual-level survival data. Additionally, marginal moment-balancing weights can adjust for differences in the distributions of patient characteristics between the trial and EHR cohorts. We evaluated bias in hazard ratio (HR) estimates by comparing trial and EHR cohorts using survival data reconstruction and marginal moment-balancing weights through simulations and analysis of real-world data. This approach produced nearly unbiased HR estimates. In an analysis of overall survival for patients with metastatic urothelial carcinoma treated with gemcitabine-carboplatin captured in the nationwide Flatiron Health EHR-derived de-identified database and patients enrolled in a trial of the same therapy, survival was similar in the EHR and trial cohorts after using weights to balance age, sex, and performance status (HR = 0.93, 95% confidence interval (0.74, 1.18)). Overall, we conclude that this approach is feasible for comparison of trial and EHR cohorts and facilitates evaluation of outcome differences between trial and real-world populations.

Entities:  

Keywords:  Electronic health records; real world data; survival; survival reconstruction; trial; weighting

Mesh:

Year:  2021        PMID: 34756156      PMCID: PMC9085966          DOI: 10.1080/10543406.2021.1998097

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.503


  19 in total

1.  Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

Authors:  Maria De Santis; Joaquim Bellmunt; Graham Mead; J Martijn Kerst; Michael Leahy; Pablo Maroto; Thierry Gil; Sandrine Marreaud; Gedske Daugaard; Iwona Skoneczna; Sandra Collette; Julie Lorent; Ronald de Wit; Richard Sylvester
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Disparities in participation in cancer clinical trials in the United States : a symptom of a healthcare system in crisis.

Authors:  Gerardo Colon-Otero; Robert C Smallridge; Lawrence A Solberg; Thomas D Keith; Timothy A Woodward; Floyd B Willis; Ajani N Dunn
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

3.  Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study.

Authors:  Ronak Saluja; Sierra Cheng; Keemo Althea Delos Santos; Kelvin K W Chan
Journal:  Res Synth Methods       Date:  2019-06-24       Impact factor: 5.273

4.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

Authors:  D F Bajorin; P M Dodd; M Mazumdar; M Fazzari; J A McCaffrey; H I Scher; H Herr; G Higgins; M G Boyle
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

5.  Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.

Authors:  Herbert H Pang; Xiaofei Wang; Thomas E Stinchcombe; Melisa L Wong; Perry Cheng; Apar Kishor Ganti; Daniel J Sargent; Ying Zhang; Chen Hu; Sumithra J Mandrekar; Mary W Redman; Judith B Manola; Richard L Schilsky; Harvey J Cohen; Jeffrey D Bradley; Alex A Adjei; David Gandara; Suresh S Ramalingam; Everett E Vokes
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

6.  On the Assessment of Monte Carlo Error in Simulation-Based Statistical Analyses.

Authors:  Elizabeth Koehler; Elizabeth Brown; Sebastien J-P A Haneuse
Journal:  Am Stat       Date:  2009-05-01       Impact factor: 8.710

7.  Using electronic health record data to identify comparator populations for comparative effectiveness research.

Authors:  Scott D Ramsey; Blythe J Adamson; Xiaoliang Wang; Danielle Bargo; Shrujal S Baxi; Shuhag Ghosh; Neal J Meropol
Journal:  J Med Econ       Date:  2020-11-10       Impact factor: 2.448

8.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.

Authors:  Xiang Wan; Wenqian Wang; Jiming Liu; Tiejun Tong
Journal:  BMC Med Res Methodol       Date:  2014-12-19       Impact factor: 4.615

9.  An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records database.

Authors:  Gillis Carrigan; Samuel Whipple; Michael D Taylor; Aracelis Z Torres; Anala Gossai; Brandon Arnieri; Melisa Tucker; Philip P Hofmeister; Peter Lambert; Sandra D Griffith; William B Capra
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-03-14       Impact factor: 2.890

10.  Development and Validation of a High-Quality Composite Real-World Mortality Endpoint.

Authors:  Melissa D Curtis; Sandra D Griffith; Melisa Tucker; Michael D Taylor; William B Capra; Gillis Carrigan; Ben Holzman; Aracelis Z Torres; Paul You; Brandon Arnieri; Amy P Abernethy
Journal:  Health Serv Res       Date:  2018-05-14       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.